Patient Leaflet Updated 03-Nov-2025 | A. Menarini Farmaceutica Internazionale SRL
Skudexa 75 mg/25 mg film-coated tablets
Skudexa 75 mg/25 mg film-coated tablets
tramadol hydrochloride/dexketoprofen
1. What Skudexa is and what it is used for
2. What you need to know before you take Skudexa
3. How to take Skudexa
4. Possible side effects
5. How to store Skudexa
6. Contents of the pack and other information
Skudexa contains the active substances tramadol hydrochloride and dexketoprofen.
Tramadol hydrochloride is a pain killer belonging to a group of medicines called opioids that act on the central nervous system. It relieves pain by acting on specific nerve cells of the brain and spinal cord.
Dexketoprofen is a pain killer and it belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
Skudexa is used for the symptomatic short term treatment of moderate to severe acute pain in adults.
You must talk to a doctor if you do not feel better or if you feel worse.
Talk to your doctor before taking Skudexa:
Tramadol may lead to physical and psychological addiction. When this medicine is taken for a long time, its effect may decrease, so that higher doses have to be taken (tolerance development). In patients with a tendency to abuse medicines or who are dependent on medicines, treatment with Skudexa should only be carried out for short periods and under strict medical supervision.
Tell your doctor if any of these problems occurs during Skudexa treatment or if they applied in the past.
Talk to your doctor if you experience any of the following symptoms while taking Skudexa: extreme fatigue, lack of appetite, severe abdominal pain, nausea, vomiting or low blood pressure. This may indicate that you have adrenal insufficiency (low cortisol levels). If you have these symptoms, contact your doctor, who will decide if you need to take hormone supplement.
Tramadol is transformed in the liver by an enzyme. Some people have a variation of this enzyme and this can affect people in different ways. In some people, they may not get enough pain relief but other people are more likely to get serious side effects. If you notice any of the following side effects, you must stop taking this medicine and seek immediate medical advice: slow or shallow breathing, confusion, sleepiness, small pupils, feeling or being sick, constipation, lack of appetite.
There is a small risk that you may experience a so-called serotonin syndrome that can occur after having taken tramadol in combination with certain antidepressants or tramadol alone. Seek medical advice immediately if you have any of the symptoms related to this serious syndrome (see section 4 “Possible side effects”).
Skudexa can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.
Skudexa may hide signs of infections such as fever and pain. It is therefore possible Skudexa may delay appropriate treatment of infection, which may lead to an increased risk of complications. This has been observed in pneumonia caused by bacteria and bacterial skin infections related to chickenpox. If you take this medicine while you have an infection and your symptoms of the infection persist or worsen, consult a doctor without delay.
During chicken pox it is advisable to avoid use of this medicine.
This medicine has not been studied in children and adolescents. Therefore, safety and efficacy have not been established and the product should not be used in children and adolescents.
Use in children with breathing problems
Tramadol is not recommended in children with breathing problems, since the symptoms of tramadol toxicity may be worse in these children.
Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. Some medicines should not be taken together and others may need their doses to be altered when taken together.
Always inform your doctor if you are using or receiving any of the following medicines in addition to Skudexa:
Use with Skudexa is not recommended:
Use with Skudexa requires precautions:
Use with Skudexa requires care:
The pain-relieving effect of tramadol may be reduced, and the length of time it acts may be shortened, if you also take medicines containing:
The risk of side effects increases
Do not drink alcohol during treatment with Skudexa as it may increase the effect of the medication. For the instruction how to take Skudexa see section 3.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Dexketoprofen can cause kidney and heart problems in your unborn baby. It may affect your and your baby’s tendency to bleed and cause labour to be later or longer than expected. From 20 weeks of pregnancy, dexketoprofen can cause kidney problems in your unborn baby, that may lead to low levels of amniotic fluid that surrounds the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the heart of the baby.
Tramadol is excreted into breast milk.
The use of Skudexa is contraindicated in pregnancy as well as during breast-feeding.
Skudexa may affect your ability to drive and handle machines, due to the possibility of dizziness, blurred vision or drowsiness as side effects of treatment. This applies particularly when Skudexa is taken with medicines that affect mood and emotions, or alcohol.
If you are affected, do not drive or use machines until the symptoms wear off.
This medicinal product contains less than 1 mmol sodium (23mg) per dosage unit, that is to say essentially “sodium-free”.
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
The lowest effective dose should be used for the shortest duration necessary to relieve symptoms. If you have an infection, consult a doctor without delay if symptoms (such as fever and pain) persist or worsen (see section 2).
The dose of Skudexa that you need depends on the type, severity and duration of your pain. Your doctor will tell you how many tablets you must take daily, and for how long.
The recommended dose is generally 1 film-coated tablet (corresponding to 75 mg of tramadol hydrochloride and 25 mg of dexketoprofen) every 8 hours, with no more than 3 film-coated tablets daily (corresponding to 225 mg of tramadol hydrochloride and 75 mg of dexketoprofen) and not exceeding 5 days of treatment.
Skudexa is not suitable for children and adolescents.
If you are aged 75 years or over, your doctor may recommend prolonging the dosage interval because your body may handle the drug more slowly.
Patients with severe liver and/or kidney insufficiency should not take Skudexa.
In case of renal dysfunction, if in your case the insufficiency is mild, your doctor may recommend prolonging the dosage interval.
In case of hepatic dysfunction, if in your case the insufficiency is mild or moderate, your doctor may recommend prolonging the dosage interval.
Swallow the tablet with a sufficient amount of fluid (preferably with a glass of water). Food delays the absorption of Skudexa, so for a faster effect take the tablet at least 30 minutes before meals. The score line is to help you break the tablet if you have difficulty swallowing it whole.
If you use too much of this medicine, tell your doctor immediately or go to the emergency department of your nearest hospital. Please remember to take this medicine pack or this leaflet with you.
The symptoms of an overdose of this medicine are:
Do not take a double dose to make up for a forgotten tablet. Take the next regular dose when it is due (see section 3 “How to take Skudexa”).
Generally there will be no after-effects when treatment with Skudexa is stopped.
However, on rare occasions, patients who have been taking Skudexa tablets for some time may feel unwell if they stop taking them abruptly. They may feel agitated, anxious, nervous or shaky, be confused, hyperactive, have difficulty sleeping and have stomach or bowel disorders. Rarely, people may get panic attacks, hallucinations, delusions, paranoia or feel a loss of identity. They may experience unusual perceptions such as itching, tingling and numbness, and ringing in the ears (tinnitus). Further unusual symptoms, i.e. confusion, delusions, feeling as though you are detached from yourself (depersonalization), and change in perception of reality (derealisation) and delusion of persecution (paranoia) have been seen very rarely. If you experience any of these complaints after stopping Skudexa, please consult your doctor.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Possible side effects are listed below according to how likely they are to occur.
You should see a doctor immediately if you experience symptoms of an allergic reaction such as swollen face, tongue and/or throat, and/or difficulty swallowing or hives together with difficulties in breathing.
Stop using Skudexa as soon as you notice the appearance of a skin rash, or any lesion inside the mouth or on mucous membranes, or any sign of an allergy.
Very common (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Psychological side effects may occur after treatment with Skudexa. Their intensity and nature may vary (according to the patient's personality and length of therapy):
Worsening of asthma has been reported.
When treatment is stopped abruptly signs of withdrawal may appear (see "If you stop taking Skudexa").
Epileptic fits have occurred mainly at high doses of tramadol or when tramadol was taken at the same time as other medicines which may induce fits.
Very rare (may affect up to 1 in 10,000 people):
Not known (frequency cannot be estimated from the available data):
Tell your doctor immediately if you experience stomach/bowel side effects at the start of treatment (e.g. stomach pain, heartburn or bleeding), if you have previously suffered from any such side effects due to long-term use of anti-inflammatory drugs, and especially if you are elderly.
The most common side effects during treatment with Skudexa are nausea and dizziness, which occur in more than 1 out of 10 patients.
During treatment with NSAIDs, fluid retention and swelling (especially in the ankles and legs), increased blood pressure and heart failure have been reported.
Medicines such as Skudexa may be associated with a small increased risk of heart attack or stroke.
In patients with immune system disorders that affect connective tissue (systemic lupus erythematosus or mixed connective tissue disease), anti-inflammatory medicines may rarely cause fever, headache and neck stiffness.
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.
The expiry date refers to the last day of that month.
This medicine does not require any special temperature storage conditions.
Store in the original package, in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Almost white to slightly yellow, oblong, film-coated tablets with a break-mark on one side and debossed “M” on the other side in plastic/aluminium push-through pill packs.
Skudexa is supplied in packs containing 2, 4, 10, 15, 20, 30, 50 or 100 film-coated tablets and in multipacks comprising 5 cartons, each containing 100 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder:
Manufacturer:
This medicinal product is authorised in the Member States of the EEA under the following names:
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovak Republic, Slovenia, Sweden, United Kingdom (Northern Ireland): Skudexa
France: Skudexum
Italy: Lenizak
Spain: Enanplus
This leaflet was last revised in 09/2024.
Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, Buckinghamshire, HP10 0HH
0800 085 8678
0800 085 8678
0800 085 8678